Chengdu, China

Pingming Tang

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 13.4

ph-index = 1

Forward Citations = 2(Granted Patents)


Location History:

  • Chengdu, CN (2023)
  • Sichuan, CN (2023)

Company Filing History:


Years Active: 2023-2025

Loading Chart...
Loading Chart...
3 patents (USPTO):

Title: Innovations of Pingming Tang in Pharmaceutical Development

Introduction

Pingming Tang is a notable inventor based in Chengdu, China, recognized for his contributions to pharmaceutical innovations. With a total of three patents to his name, he has made significant strides in the field of drug development, particularly in the treatment of respiratory diseases.

Latest Patents

Among his latest patents is a nitrile derivative that acts as an inhibitor of dipeptidyl peptidase 1. This compound, represented by a specific formula, includes various forms such as stereoisomers, deuterated products, co-crystals, solvates, or pharmaceutically acceptable salts. The compound exhibits dipeptidyl peptidase 1 inhibitory activity, making it a potential candidate for developing drugs aimed at treating obstructive airway diseases, bronchiectasis, cystic fibrosis, asthma, emphysema, and chronic obstructive pulmonary diseases.

Career Highlights

Pingming Tang is currently associated with Haisco Pharmaceuticals Pte. Ltd., where he continues to innovate and contribute to the pharmaceutical industry. His work focuses on developing effective treatments for complex diseases, showcasing his commitment to improving patient outcomes.

Collaborations

He collaborates with talented coworkers, including Yao Li and Fei Ye, who contribute to his research and development efforts. Their combined expertise enhances the potential for groundbreaking discoveries in the pharmaceutical field.

Conclusion

Pingming Tang's innovative work in developing nitrile derivatives for treating respiratory diseases highlights his significant impact on the pharmaceutical industry. His contributions are paving the way for new therapeutic options that could benefit many patients worldwide.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…